Raymond Andersen

Key Research Areas
Associated Researchers
Associated Organizations

Recent Research Projects

NSERC CREATE Collaborative Medicinal Chemistry Network in Epigenetics Training (ChemNET):Training Canadian chemists within a global open access public-private partnership

2013/14-2018/19 • $1,554,496 • PI,CO
The proposed CREATE program (Medicinal Chemistry Network in Epigenetics Training; ChemNET) willtrain the next generation of medicinal chemists within an open access, international research collaboration involving four Canadian universities, the Structural Genomics Consortium (SGC) - a...

Bioactivity Guided Marine Natural Product Discovery Using Phenotypic Assays

2018/19 • $48,000 • PI
The main objective of the proposed research will be to use Forward Chemical Genetics cell-based phenotypic assay screening platforms to facilitate the discovery of structurally novel bioactive marine natural products (MNPs) that can be used as tools in basic biological studies of i) MHC-1...

A Chemical Genetics Approach to the Discovery and Synthesis of Bioactive Marine Natural Products

2013/14-2017/18 • $495,000 • PI
The main objective of the proposal will be to use a chemical genetics approach to discover new bioactive marine natural products (MNPs) that can be used as tools in fundamental studies of autophagy, MRSA hub proteins, histone methylation, and F508del-CFTR correction. A secondary objective will...

Operations and Maintenance Support: UBC Regional Structural Biology Facility

2016/17-2017/18 • $300,000 • PI,CO
Structural biology is a branch of the Life Sciences that seeks to provide atomic-level descriptions of the three-dimensional structures of biological molecules, including proteins, DNA, RNA and sugars. This structural information is critical for understanding the diverse functions of these...

High Resolution ESI Mass Spectrometer

2017/18 • $150,000 • PI,CO
We request funds to purchase a high resolution electrospray ionization mass spectrometer (HR-ESI-MS). This HR-ESI-MS will be operated and maintained in the UBC Chemistry Mass Spectrometry Facility, where it will replace a 19 year old, faltering instrument. This previous instrument has been...

High Resolution EI Mass Spectrometer

2016/17 • $150,000 • PI,CO
This proposal is to obtain a high resolution EI mass spectrometer for the analysis of non-polar organic compounds and organometallics. Mass spectrometry is a powerful analytical technique that is used to identify unknown compounds, to quantify known compounds, and to elucidate the structure and...

UBC Chemistry X-ray Diffractometer Upgrade

2014/15 • $150,000 • PI,CO
This application requests funds to upgrade a single-crystal X-ray diffractometer purchased in 2003. The addition of a new molybdenum (Mo) source and repairs to the CCD detector by the manufacturer will accomplish the following: (i) expand the types of crystals that can be examined by this...

isolation, structure elucidation and synthesis of biologically active marine natural products

2010/11-2012/13 • $240,000 • PI
The objective of the proposed research will be to discover structurally novel marine natural products that can be used as chemical tools in cell biology and whole animal investigations of autophagy, miRNA gene silencing, and toll-like-receptor-5 (TLR5) signaling. Organic synthesis will be used...

Chemical correctors of deltaF508 CFTR trafficking

2010/11-2011/12 • $244,076 • PI,CO
No summary

NANUC: a national facility for high field NMR resource for applications in chemistry

2010/11 • $220,000 • PI,CO
The National High Field NMR Centre, NANUC, is a publicly accessible scientific resource providing NMR research services, support, training and outreach to a broad constituency of Canadian academic and industrial users. The Centre offers access to very high field magnetic resonance technology and...

A vessel for oceanic and limnological research

2010/11 • $99,482 • PI,CO
A fundamental requirement for research in aquatic sciences is a means to gather samples from natural bodies of water. The dept. of Earth and Ocean Sciences at UBC maintains a trailer-towed 21' aluminum workboat (purchased in 1993) which has been well used in coastal and inland waters of British...

Patents

SHIP 1 MODULATOR COMPOUNDS

The present invention provides the use of pelorol analogs of Formula, ( I ) and pharmaceutical compositions thereof as modulators of SHIP 1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hemato poetic or immune disorder or condition in addition to other disorders and co nditions.
Related applications: WO2007CA01106, EP20070720020, CA20072656333, EP20070720021, CA20072656339, WO2007CA01105

SMALL MOLECULE CORRECTORS OF DELTAF508 CFTR TRAFFICKING

This invention provides compounds of Formula I. The compounds are correctors of ?F508 CFTR trafficking. Also provided are uses of compounds of Formula I for treatment, as well as methods of treatment, of cystic fibrosis.
Related applications: CA20082728366, EP20080783175, WO2008CA01238

ALPHA-AMYLASE INHIBITORS: THE MONTBRETINS AND USES THEREOF

Particular naturally occurring glycosylated acyl-flavonols, e.g. montbretm A (of the formula below wherein R1, R2, R3, R5, R5', and R7 is OH each, X is ß-D-glucopyranosyl), are now shown to be effective mammalian a-amylase inhibitors Such compounds can be obtained from plants of the genus Crocosmia The compounds and their analogs of the formula below are useful in controlling starch digestion such as for management of glycermia in pre-diabetic or diabetic subjects, for management of obesity...
Related applications: EP20080839507, WO2008CA01901, CA20082738834

DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE

This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Related applications: EP20090771876, EP20170177010, EP20090771876, WO2009CA00902, CA20092728219, ES20090771876T

SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR

Compounds having a structure of Formula (A) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided. Uses of compounds having a structure of Formula (F) for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Related applications: ES20090807798T, CA20092728103, WO2009CA01173, EP20090807798

BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS

This invention provides bisphenol derivatives having a structure of formula I. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and air loss.
Related applications: WO2011CA00019, EP20110731645, CA20112786319, EP20110731645

BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE

This invention provides compounds having a structure of Formula (I). Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Related applications: WO2011CA00021

SHIP1 MODULATORS AND RELATED METHODS

Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in...
Related applications: ES20110818895T, EP20110818895, WO2011US48650

FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, and wherein at least one of R1, R2, R3, R4 or R5 is F, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Related applications: WO2012US51481, EP20120762710, ES20120762710T

BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE

Compounds having a structure of Formula I: wherein G, a, Q, L2, R1, R2, R3, R4, R5 and R6 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Related applications: WO2012US32584, EP20120768410

DIBENZYLPHENYL COMPOUNDS AND METHODS FOR THEIR USE

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, R1 and R2 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Related applications: WO2012US33957

FLUORENE-9-BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt or tautomer thereof, wherein Z1, Z2, Z3 and Z4 are as defined herein. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Related applications: WO2012US33959

COMPOSÉS 18F POUR IMAGERIE DU CANCER ET LEURS PROCÉDÉS D'UTILISATION

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, Z, X and n are as defined herein, and wherein the compound comprises at least one 18F moiety, are provided. Uses of such compounds for imaging diagnostics in cancer, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
Related applications: WO2012US51923

ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE

Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
Related applications: WO2015US33385, CA20152948643, EP20150728354

BIS-INDOLE ALKALOIDS FOR USE IN THE TREATMENT OF INFECTIONS

The present application describes bisindole alkaloids of formulas I and II and pharmaceutical compositions thereof useful in the treatment of bacterial infection such as Staphylococcus aureus (MRSA) infection: wherein X1 is: wherein X2 is:
Related applications: WO2015CA00468

18F COMPOUNDS FOR CANCER IMAGING AND METHODS FOR THEIR USE

Compounds having a structure of Formula I: (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, Z, X and n are as defined herein, and wherein the compound comprises at least one 18F moiety, are provided. Uses of such compounds for imaging diagnostics in cancer, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
Related applications: WO2015CA00535

MEROTERPENOID COMPOUNDS, METHODS AND COMPOSITIONS FOR THEIR USE IN INSECT CONTROL

The invention provides in part dhilirolide compounds for insect control, for such insects as Trichoplusia ni, and methods thereof. The compounds include compounds of Formula I.
Related applications: WO2015CA00198

MAMMALIAN GLUCOSIDASE INHIBITORS, METHODS FOR THEIR USE AND PHARMACEUTICAL COMPOSITIONS THEREOF

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a Helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: Middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus...
Related applications: WO2016CA00183, CA20163029064

BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS

Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
Related applications: CA20173021008